{"id":1077,"date":"2022-03-21T23:09:19","date_gmt":"2022-03-21T23:09:19","guid":{"rendered":"https:\/\/linksus.net\/blood-test-may-predict-long-term-risk-of-diabetes-and-heart-disease-medical-news-today\/"},"modified":"2022-03-21T23:09:19","modified_gmt":"2022-03-21T23:09:19","slug":"blood-test-may-predict-long-term-risk-of-diabetes-and-heart-disease-medical-news-today","status":"publish","type":"post","link":"https:\/\/linksus2.linksus.net\/index.php\/2022\/03\/21\/blood-test-may-predict-long-term-risk-of-diabetes-and-heart-disease-medical-news-today\/","title":{"rendered":"Blood test may predict long-term risk of diabetes and heart disease – Medical News Today"},"content":{"rendered":"

In the United States, 1 in 10 people<\/a><\/hl-trusted-source> has type 2 diabetes<\/a>. Someone dies every 36 seconds from cardiovascular disease (CVD)<\/a> in the U.S., and CVD causes one-third of all deaths<\/a><\/hl-trusted-source> worldwide.
Both conditions may develop slowly, and the symptoms are not always evident. Doctors assess a person\u2019s risk of developing them by taking a patient history and observing current lifestyle factors.
Now, a study led by Prof. Dr. Chris Lauber,<\/a> of Twincore<\/a> in Germany, has shown that lipids in blood plasma can predict future risk of type 2 diabetes and CVD.
The method \u2014 known as lipidomic profiling<\/a><\/hl-trusted-source> \u2014 can provide a quantitative measurement of risk long before symptoms develop.
\u201cThe authors of this study have added to the growing evidence that lipidomics profiling could very well usher in the next generation of detection of cardiovascular diseases as well as diabetes.\u201d
\u2013 Dr. Suneet Singh<\/a>, Medical Director of CareHive.
The longitudinal study included just over 4,000 healthy, middle-aged Swedish people from the Malm\u00f6 Diet and Cancer-Cardiovascular Cohort<\/a><\/hl-trusted-source>.
Participants ranged from 46\u201368 years at the start of the study. Around 10% had a body mass index (BMI)<\/a> of more than 30.
The researchers took one baseline blood sample from each participant. They then centrifuged these blood samples to separate out the plasma for analysis.
Researchers measured concentrations of 184 different lipids in the blood plasma using mass spectrometry<\/a><\/hl-trusted-source>. They used these lipidomic profiles<\/a><\/hl-trusted-source> to calculate risk scores and assign participants into one of six risk groups.
Dr. Singh told Medical News Today<\/em> the study could add to previous methods of assessing risk:
\u201cThis new approach allows for a novel framework of risk stratification which also allows for enhancement when used in conjunction with the measurement of standard clinical variables.\u201d<\/strong>
He did, however, note that there was little diversity in the study population: \u201cIt is advisable to continue to expand upon this research by increasing the patient population to include several more variables. This includes different patient ages, racial groups, ethnicities, and physical activity levels.\u201d
The researchers followed up participants for more than 20 years from baseline assessments made between 1991 and 1994. In that time, 13.8% of the cohort developed type 2 diabetes, and 22% developed CVD.
For those in the highest risk groups, these values rise to 37% for developing type 2 diabetes and 40.5% for developing CVD as compared to the group averages above.<\/strong><\/strong>
People in the lowest risk groups had a decreased risk of developing both conditions.
The researchers also found that people with high lipid risk scores had a much greater likelihood of developing obesity during the follow-up period. Obesity is a risk factor<\/a><\/hl-trusted-source> for both type 2 diabetes and CVD.
The authors suggest that this risk-score-based approach could indicate the risk of both type 2 diabetes and CVD many years before disease onset. <\/strong>
\u201c[T]his earlier disease detection occurs at a time where the disease has not become clinically evident. As a result, researchers and clinicians can now take on diseases from a more proactive preventive lens and not simply one that starts at the treatment stage,\u201d Dr. Singh commented.
Using mass spectrometry to measure blood plasma lipids is quick, relatively inexpensive, and gives quantitative results.
The authors of this study suggest that it could identify lipids that contribute most to the risk of developing subsequent health conditions and, potentially, lead to new drug treatments.
Dr. Singh told MNT<\/em>: \u201cResearch [\u2026] demonstrated in this paper helps to advance the field of clinical mass spectrometry as a whole by continuing to demonstrate the potential for earlier disease detection in advance of conventional means.\u201d
The authors stress that further research is needed to verify their hypothesis and demonstrate how informative the plasma lipidome is for health and disease.
\u201cThe lipidome may provide insights much beyond diabetes and cardiovascular disease risk.\u201d
\u2013 Prof. Chris Lauber, lead author of the study.
So, this simple test could tell people their risk of developing both type 2 diabetes and CVD. By making diet and lifestyle changes, they may then be able to decrease that risk.
In this edition of Medical Myths, we address five persistent myths about obesity. This article covers genetics, weight loss, diabetes, and more.<\/a>
In this edition of Medical Myths, we investigate 11 misconceptions about weight loss. We cover sugar and sweeteners, skipping meals, snacking, and\u2026<\/a>
When it comes to health, not all fats are equal. This article looks at the sources and types of fat, their effects on the body, and how much to add to\u2026<\/a>
Lipid disorders, such as high cholesterol, are common in the United States. Learn more about lipid disorders, their diagnosis, treatment, and more.<\/a>
Which foods are healthful? Which foods should we avoid? In this feature, we ask why the results of nutrition studies are so contradictory and\u2026<\/a>
OUR BRANDS<\/p>\n

source<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

In the United States, 1 in 10 people has type 2 diabetes. Someone dies every 36 seconds from cardiovascular disease (CVD) in the U.S., and CVD causes one-third of all deaths worldwide.Both conditions may develop slowly, and the symptoms are not always evident. Doctors assess a person\u2019s risk of developing them by taking a patient […]<\/p>\n","protected":false},"author":869,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[],"tags":[],"_links":{"self":[{"href":"https:\/\/linksus2.linksus.net\/index.php\/wp-json\/wp\/v2\/posts\/1077"}],"collection":[{"href":"https:\/\/linksus2.linksus.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/linksus2.linksus.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/linksus2.linksus.net\/index.php\/wp-json\/wp\/v2\/users\/869"}],"replies":[{"embeddable":true,"href":"https:\/\/linksus2.linksus.net\/index.php\/wp-json\/wp\/v2\/comments?post=1077"}],"version-history":[{"count":0,"href":"https:\/\/linksus2.linksus.net\/index.php\/wp-json\/wp\/v2\/posts\/1077\/revisions"}],"wp:attachment":[{"href":"https:\/\/linksus2.linksus.net\/index.php\/wp-json\/wp\/v2\/media?parent=1077"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/linksus2.linksus.net\/index.php\/wp-json\/wp\/v2\/categories?post=1077"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/linksus2.linksus.net\/index.php\/wp-json\/wp\/v2\/tags?post=1077"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}